全文获取类型
收费全文 | 3047篇 |
免费 | 217篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 52篇 |
妇产科学 | 48篇 |
基础医学 | 378篇 |
口腔科学 | 46篇 |
临床医学 | 193篇 |
内科学 | 581篇 |
皮肤病学 | 137篇 |
神经病学 | 141篇 |
特种医学 | 44篇 |
外科学 | 557篇 |
综合类 | 273篇 |
预防医学 | 182篇 |
眼科学 | 36篇 |
药学 | 293篇 |
中国医学 | 60篇 |
肿瘤学 | 285篇 |
出版年
2023年 | 54篇 |
2022年 | 61篇 |
2021年 | 114篇 |
2020年 | 101篇 |
2019年 | 214篇 |
2018年 | 172篇 |
2017年 | 112篇 |
2016年 | 75篇 |
2015年 | 90篇 |
2014年 | 181篇 |
2013年 | 164篇 |
2012年 | 117篇 |
2011年 | 179篇 |
2010年 | 140篇 |
2009年 | 167篇 |
2008年 | 137篇 |
2007年 | 145篇 |
2006年 | 141篇 |
2005年 | 107篇 |
2004年 | 89篇 |
2003年 | 95篇 |
2002年 | 54篇 |
2001年 | 64篇 |
2000年 | 46篇 |
1999年 | 35篇 |
1998年 | 28篇 |
1997年 | 25篇 |
1996年 | 20篇 |
1995年 | 23篇 |
1994年 | 15篇 |
1993年 | 10篇 |
1992年 | 12篇 |
1991年 | 12篇 |
1990年 | 5篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 22篇 |
1984年 | 49篇 |
1983年 | 29篇 |
1982年 | 42篇 |
1981年 | 32篇 |
1980年 | 26篇 |
1979年 | 22篇 |
1978年 | 18篇 |
1977年 | 6篇 |
1976年 | 16篇 |
1975年 | 17篇 |
1974年 | 9篇 |
1973年 | 7篇 |
排序方式: 共有3332条查询结果,搜索用时 140 毫秒
1.
《Injury》2023,54(7):110767
AimThis network meta-analysis aims to compare functional outcomes and complications between conservative treatment and surgery for distal radius fractures in patients aged 60 years and over.MethodsWe searched the PubMed, EMBASE, and Web of Science databases for randomized controlled trials (RCTs) assessing the effect of conservative treatment and surgery for distal radius fractures in patients aged 60 years and over. Primary outcomes included grip strength and overall complications. Secondary outcomes included Disabilities of the Arm, Shoulder, and Hand (DASH) scores, Patient-Rated Wrist Evaluation (PRWE) scores, wrist range of motion and forearm rotation, and radiographic assessment. All continuous outcomes were assessed using standardized mean differences (SMDs) with 95% confidence intervals (CIs), and binary outcomes were assessed using odds ratio (OR) with 95% CIs. The surface under the cumulative ranking curve (SUCRA) was used to determine a hierarchy of treatments. Cluster analysis was performed for grouping treatments based on the SUCRA values of primary outcomes.ResultsFourteen RCTs were included to compare conservative treatment, volar lockedplate (VLP), K-wires fixation, and external-fixation. VLP outperformed conservative treatment for 1-year and minimum 2-year grip strength (SMD; 0.28 [0.07 to 0.48] and 0.27 [0.02 to 0.53], respectively). VLP yielded the optimal grip strength at 1-year and minimum 2-year follow-up (SUCRA; 89.8% and 86.7%, respectively). In a subgroup analysis of patients aged 60 to 80 years old, VLP outperformed conservative treatment in DASH and PRWE scores (SMD, 0.33 [0.10, 0.56] and 0.23 [0.01, 0.45], respectively). In addition, VLP had the fewest complications (SUCRA = 84.3%). Cluster analysis suggested that VLP and K-wire fixation were more effective treatment groups.ConclusionEvidence to date demonstrates that VLP provides measurable benefits in grip strength and fewer complications to those 60 years of age and over, and that benefit is not reflected in current practice guidelines. There is a subgroup of patients where K-wire fixation outcomes are similar to those of VLP; defining this subgroup may yield substantial societal benefits. 相似文献
2.
D. R. Frei R. Beasley D. Campbell A. Forbes K. Leslie D. Mackle C. Martin A. Merry M. R. Moore P. S. Myles L. Ruawai-Hamilton T. G. Short P. J. Young 《Anaesthesia》2023,78(10):1272-1284
International recommendations encourage liberal administration of oxygen to patients having surgery under general anaesthesia, ostensibly to reduce surgical site infection. However, the optimal oxygen regimen to minimise postoperative complications and enhance recovery from surgery remains uncertain. The hospital operating theatre randomised oxygen (HOT-ROX) trial is a multicentre, patient- and assessor-blinded, parallel-group, randomised clinical trial designed to assess the effect of a restricted, standard care, or liberal peri-operative oxygen therapy regimen on days alive and at home after surgery in adults undergoing prolonged non-cardiac surgery under general anaesthesia. Here, we report the findings of the internal vanguard feasibility phase of the trial undertaken in four large metropolitan hospitals in Australia and New Zealand that included the first 210 patients of a planned overall 2640 trial sample, with eight pre-specified endpoints evaluating protocol implementation and safety. We screened a total of 956 participants between 1 September 2019 and 26 January 2021, with data from 210 participants included in the analysis. Median (IQR [range]) time-weighted average intra-operative FiO2 was 0.30 (0.26–0.35 [0.20–0.59]) and 0.47 (0.44–0.51 [0.37–0.68]) for restricted and standard care, respectively (mean difference (95%CI) 0.17 (0.14–0.20), p < 0.001). Median time-weighted average intra-operative FiO2 was 0.83 (0.80–0.85 [0.70–0.91]) for liberal oxygen therapy (mean difference (95%CI) compared with standard care 0.36 (0.33–0.39), p < 0.001). All feasibility endpoints were met. There were no significant patient adverse events. These data support the feasibility of proceeding with the HOT-ROX trial without major protocol modifications. 相似文献
3.
目的探讨新型雌激素受体亚型ER-α30和ER-α36在乳腺癌中的表达及与他莫昔芬治疗预后的关系。方法收集2015年1月至2015年11月间在河北北方学院附属第一医院接受他莫昔芬内分泌治疗的Luminal A型乳腺癌患者75例,并收集同时期30例ER(-)乳腺癌患者组织。采用免疫组化染色SP法检测ER-α30和ER-α36蛋白表达。分析ER-α30和ER-α36蛋白表达与Luminal A型乳腺癌临床病理特征的关系。随访患者的无病生存时间(DFS)。采用Cox风险比例回归模型分析影响DFS的因素。结果Luminal A型乳腺癌组织中ER-α30蛋白阳性表达率为32.0%(24/75),低于ER(-)乳腺癌组织(P<0.05)。ER-α30蛋白表达与TNM分期、肿瘤直径、浸润深度、淋巴结转移、孕激素受体状态有关(P<0.05)。ER-α36蛋白阳性表达率为52.0%(39/75),与ER(-)乳腺癌组织比较差异无统计学意义(P>0.05)。ER-α36蛋白表达与TNM分期和肿瘤直径有关(P<0.05)。随访时间为11~54个月,患者48个月无病生存率为64.0%(48/75)。ER-α30阳性患者48个月无病生存率为33.33%(8/24),阴性患者为78.43%(40/51),差异具有统计学意义(P=0.001)。ER-α36阳性患者48个月无病生存率为48.7%(19/39),阴性患者为80.6%(29/36),差异具有统计学意义(P=0.002)。Cox风险比例回归分析显示,ER-α30、ER-α36是影响Luminal A型乳腺癌患者DFS的独立预后因素(P<0.05)。结论Luminal A型乳腺癌ER-α30和ER-α36阳性表达者接受他莫昔芬治疗无病生存期较短,其有望成为预测他莫昔芬治疗反应性的重要指标。 相似文献
4.
miR-30c has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and prostate cancer. However, the role of miR-30c in glioblastoma (GBM) needs to be investigated.
In our study, we found that the expression of miR-30c was significantly downregulated in GBM tissues and
cell lines. We found that overexpression of miR-30c inhibited cellular proliferation of GBM cells in vitro and
in vivo. More GBM cells were arrested in the G0 phase after miR-30c overexpression. Moreover, we showed
that miR-30c overexpression suppressed the migration and invasion of GBM cells. Mechanistically, we found
that SOX9 was a direct target of miR-30c in GBM cells. Overexpression of miR-30c inhibited the mRNA
and protein levels of SOX9 in GBM cells. Moreover, there was a negative correlation between the expression
of miR-30c and SOX9 in GBM tissues. Finally, we showed that restoration of SOX9 in GBM cells reversed
the proliferation, migration, and invasion of GBM cells transfected with miR-30c mimic. Collectively, our
results demonstrated that miR-30c suppressed the proliferation, migration, and invasion of GBM cells via
targeting SOX9. 相似文献
5.
6.
7.
Inna Y. Gong Nigel S. Tan Sammy H. Ali Gerald Lebovic Muhammad Mamdani Shaun G. Goodman Dennis T. Ko Andreas Laupacis Andrew T. Yan 《The Canadian journal of cardiology》2019,35(5):653-660
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献8.
9.
目的 探讨miR-30-5p对视网膜母细胞瘤细胞增殖的影响及作用机制。 方法 采用实时荧光定量聚合酶链式反应(qRT-PCR)检测miR-30-5p在视网膜母细胞瘤细胞系和人视网膜内皮细胞(HRECs)中的表达。利用TargetScan数据库进行生物信息学分析并预测miR-30-5p靶基因,双荧光素酶报告基因实验验证miR-30-5p与FOXG1的3'UTR结合能力及靶向关系,qRT-PCR和Western blotting分别检测miR-30-5p对FOXG1的mRNA与蛋白表达影响。瞬时转染Y79细胞后,通过CCK8法检测各组Y79细胞的增殖。 结果 与HRECs比较,miR-30-5p在视网膜母细胞瘤细胞中表达降低,FOXG1在视网膜母细胞瘤细胞中表达升高。生物信息学预测结果显示miR-30-5p与FOXG1存在结合位点,qRT-PCR和Western blotting显示miR-30-5p可负调控FOXG1的mRNA和蛋白的表达,双荧光素酶实验结果证实miR-30-5p与FOXG1 3'UTR存在靶向关系。瞬时转染miR-30-5p可升高Y79细胞中miR-30-5p的表达水平,抑制Y79细胞的增殖活力。过表达FOXG1可逆转miR-30-5p上调对Y79细胞增殖的影响。 结论 miR-30-5p通过下调FOXG1表达抑制视网膜母细胞瘤Y79细胞的增殖。 相似文献
10.
Liya Wang Feifei Chen Sha Zhao Xiaokang Wang Jiayi Fang Xiaofang Zhu 《Dermatologic therapy》2021,34(1):e14452
Lymphomatoid papulosis (LyP) is a rare CD30+ lymphoproliferative primary skin disease with a benign clinical course and malignant histopathology. LyP is classified into seven subtypes based on histopathology: subtypes A through F and LyP with 6p25.3 chromosome rearrangement. We present here, a case report of a 51‐year‐old man, afflicted with multiple papules and nodules on his left arm for over 3 months and diagnosed with LyP subtype C. The patient refused treatment, and his lesions faded with no visible rash on the left arm 14 months after diagnosis. 相似文献